TBX-3400

A NEW CLASS OF CELL THERAPY

Overview

  • Cell-based immunotherapy in clinical testing.

  • Indications: solid tumors and infectious disease.

  • .Target Dose: anticipated at 10  to 10  cells/kg

  • Treatment schedule: 2-week or 4-week schedule.

  • Manufacturing: a 4-hour process which yields up to 16 doses that can be cryopreserved.

5

6

Key Milestones

  • Active US Phase I/II clinical trial for Stage 3 & 4 Melanoma.

  • Active US & Israel Phase I/II clinical trial for solid tumors.

  • First-in-human Safety Study data approved by Japan’s MHLW.

  • Active Efficacy Study for Hepatitis B and Hepatocellular Carcinoma.

  • US Orphan Drug Designation for Melanoma.

Taiga_Graphics_Powerpoint_v1_edited.jpg

1. Blood Collection: blood is drawn from the patient in a hospital or clinic in an outpatient setting.

2. Processing: Immune cells are separated and the white blood cells are treated with TBX-4000 protein.

3. Treatment: the treated cells are then returned to the patient.

TREATING THE PATIENT

process1_edited.jpg

Greater Access to Patients

  • No longer need the patient to be present, only the patient’s cells.

  • Eliminates the toll on the patient of recurring blood draws.

  • Cells can be shipped around the world, processed, and sent back.

  • Regional Cell Processing Centers.

Significant Cost Savings

  • Cryopreservation reduces the number of manufacturing runs per patient.

  • The cost of manufacturing declines by over 75%.

  • Improved scheduling and logistics.

  • Makes cell therapies affordable.